Adapt Faces Tough Questions in Bid to Revive Narcan Patents

Adapt Pharma Inc.'s arguments were met with skepticism from two judges as it tried to convince the Federal Circuit to revive its four patents on Narcan opioid overdose treatment felled by Teva Pharmaceuticals USA Inc.

A ruling from the U.S. District Court for the District of New Jersey invalidated the patents as obvious, paving the way for drug companies like Teva to make generic versions of the nasal spray 15 years earlier than if the patents were allowed to expire.

Emergent BioSolutions subsidiary Adapt spent the bulk of its argument time at the U.S. Court of Appeals for the Federal ...